BrainsWay recently announced that it closed an underwritten public offering worth approximately $45.2 million in proceeds. The non-invasive brain disorder treatment developer offered more than 5.3 million American Depositary Shares (ADSs), upsized to include 693,300 ADSs sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares at $8.50 per share, […]
Brainsway
Former Dynatronics CEO to take corner office at BrainsWay
Neuromodulation therapy developer BrainsWay (NSDQ:BWAY) announced that it appointed former Dynatronics CEO Christopher von Jako as president and CEO. The company’s board of directors said von Jako, who will assume the role in January 2020, will be central to Brainsway’s strategic transition to U.S.-based leadership. Prior to his role as CEO of Dynatronics, von Jako served […]
These 10 medtech companies care a lot about research
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal year. We […]
BrainsWay touts results of dTMS study for depression
BrainsWay (NSDQ:BWAY) said today that a study shows that deep transcranial magnetic stimulation (dTMS) plus standard medication was significantly more effective at reducing depression levels among major depressive disorder (MDD) patients than standard medication alone. Researchers at the Psychiatric Hospital Sveti Ivan in Croatia conducted the 228-patient randomized controlled study independent of industry support. The […]
Brainsway prices downsized $28m IPO
Brainsway yesterday priced its initial public offering in the U.S. slightly below the terms it set earlier this month. The Jerusalem-based company, which is already publicly traded in Israel, said April 3 that it planned to float 2.5 million American Depository shares at roughly $11.94 apiece. Each ADS is would represent two ordinary shares, slated […]
Brainsway sets terms for $30m IPO
Brainsway this week set the terms on its forthcoming initial public offering in the U.S., saying it hopes to raise nearly $30 million. The Jerusalem-based company, which developed a transcranial magnetic stimulation device to treat psychological disorders, said it plans to float 2.5 million American Depository shares at roughly $11.94 apiece. Each ADS is slated […]
Brainsway registers for $30m IPO
Brainsway has registered for an upcoming initial public offering, looking to bring in $30 million to support its transcranial magnetic stimulation tech, according to a recently posed SEC filing. The Israel-based company said that it plans to list on the Nasdaq Global Market under the symbol “BWAY,” according to the filing. Brainsway develops and supports […]
FDA chooses 8 medtech companies for opioid crisis challenge
The FDA has selected eight medtech companies to develop devices to help reduce the country’s opioid abuse crisis. More than 250 companies submitted entries to the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder, announced in May. Those selected include Masimo Corp. and deep-brain-stimulation company Brainsway Ltd. The companies will be expected to […]
BrainsWay wins ‘historic milestone’ clearance to treat OCD
BrainsWay said it has won de novo clearance from the FDA for its deep transcranial magnetic stimulation (Deep TMS) system for treatment of obsessive-compulsive disorder (OCD) in adults. The clearance marks the second indication granted for BrainsWay Deep TMS, and the first noninvasive medical device clearance for the treatment of OCD. The FDA cleared the device […]
Brainsway wins FDA nod for OCD-treating TMS system
The FDA today said it granted de novo approval for Brainsway‘s deep transcranial magnetic stimulation system, now indicated for treating obsessive compulsive disorder. The TMS system uses magnetic fields to simulate nerves in the brain, and has been shown to reduce the severity of OCD in patients. A 100-patient randomized, multi-center study of the device […]
7 medtech stories we missed this week: May 11, 2018
From ReShape submitting an approval application to Health Canada to Conavi receiving FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. ReShape submits for Health Canada approval of ReShape balloon ReShape announced in a May 10 press release that it has submitted an application to the Medical Devices Bureau […]
